At Usona, our exploration of psychedelic compounds is guided by discovery through scientific rigor. Our Medicinal Chemistry team continues publishing impactful research articles in collaboration with scientists around the globe.
Usona Publications
Neuropharmacological Advances: Harnessing 5-HT2A Receptor Modulators and Psychoplastogens
Kargbo, R. B. ACS Med. Chem. Lett. 2024, DOI:org/10.1021/acsmedchemlett.4c00003
Perceptual Modifying Compounds and Their Potential Therapeutic Applications in Neuropsychiatric Disorders
Kargbo, R. B. ACS Med. Chem. Lett. 2024, 15 (1), 12–14
Small-Molecule Heterocyclic Compounds: Gq-Biased Agonists for the 5-HT2A Receptor in Neuropsychiatric Treatment
Kargbo, R. B. ACS Med. Chem. Lett. 2023, 14 (11), 1498–1500
Neurosteroids and Postpartum Depression: The Mechanism, Efficacy, and Approval of Brexanolone and Zurzuvae
Kargbo, R. B. ACS Med. Chem. Lett. 2023, 14 (10), 1326–1328
Microbiome: The Next Frontier in Psychedelic Renaissance
Kargbo, R. B. J. Xenobiot. 2023, 13 (3), 386-401.
Swim in the Chiral Pool: MDMA and MDA Enantiomers from Alanine-Derived Precursors
Sherwood, A. M.; Burkhartzmeyer, E. K.; Williamson, S. E.; Faley, M. T. ACS Omega 2023, 8 (24), 22132–22137.
5-MeO-DMT Modifies Innate Behaviors and Promotes Structural Neural Plasticity in Mice
Jefferson, S. J.; Gregg, I.; Dibbs, M.; Liao, C.; Wu, H.; Davoudian, P. A.; Woodburn, S. C.; Wehrle, P. H.; Sprouse, J. S.; Sherwood, A. M.; Kaye, A. P.; Pittenger, C.; Kwan, A. C. Neuropsychopharmacology 2023, 48 (9), 1257–1266.
Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?
Cotten, S. W.; Strathmann, F. G.; Barrett, F. S.; Labay, L.; Mullally, J.; Sherwood, A. M.; Wiegand, F. Clin. Chem. 2023, 69 (4), 319–326.
Our Mission and Vision
Get more information about our Medicinal Chemistry team and our work with synthetic processes and psychedelic compounds.
